AbbyBrenaSiegelMD

Oncology • New York, NY

Gastrointestinal Cancer, Hematologic Oncology

Assistant Professor, Medicine, Columbia University College of Physicians & Surgeons

Join to view full profile

Dr. Siegel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Siegel's full profile

Already have an account?

Office
1305 York Ave
Fl 12
New York, NY 10021
Phone+1 646-962-6200

Fax+1 646-962-1607

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2002 - 2004
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
University of Massachusetts Medical SchoolClass of 1997

Certifications & Licensure

NY State Medical License 1999 - 2024
CT State Medical License 2010 - 2019

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2012 Dec 01
Completed
Phase 2
S1204, Viral Screening in Newly Diagnosed Cancer Patients Start of enrollment: 2013 Aug 29
Completed
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1594 citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
The Lancet. Oncology. 2018-07-01
1055 citations
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour
Journal of Clinical Oncology. 2020-01-20
48 citations
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Masatoshi Kudo, Richard S Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara
European Journal of Cancer. 2022-05-01

Press Mentions

'Brave, Compassionate and Dedicated': ER Doctor Who Treated Coronavirus Patients Dies by SuicideApril 29th, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member